Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com.
China is one of the most important strategic markets for Boehringer Ingelheim. The company aims to bring more and better innovative products and solutions earlier to the Chinese patients, contribute to the high-quality development of China’s healthcare industry, and comprehensively improve the health of human and animals. Boehringer Ingelheim China headquarters in Shanghai with more than 4,000 employees. In recent years, the company has achieved continuous growth and has been certified as “China Top Employer” during 2014 to 2022.
Qiming Venture Partners
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages
Since our debut, we have backed over 480 fast-growing and innovative companies. Over 180 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.
Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE: ZH, SEHK: 2390), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schr.dinger (NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606), Venus MedTech (SEHK:2500), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), Yuanxin Technology, dMed-Clinipace, Belief BioMed, WeRide, Biren Technology and UBTech, among many others.
Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of €19.7 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
Merck has been in China for 89 years. As an important part of Merck’s global innovation network, Merck China Innovation Hub scouts, incubates and invests in innovative opportunities in healthcare, life science, electronics and related fields. Merck Innovation Hub China is committed to partnering with start-ups, academic institutions, industry players and local governments, combining unique technology and expertise from Merck Group and collaborators with the goal to develop novel technology and bring new solutions to the market for China and global. Learn more at http://innovateinchina.merckgroup.com.
The Galien Foundation
Founded in France 50 years ago by pharmacist Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien supports, recognizes and awards the efforts of scientists, researchers and companies committed to advancing medical innovation with the power to change the human condition. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. Our non-profit 501(c)(3) Foundation oversees and directs activities in the United States for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. For more information, please visit: https://www.galienfoundation.org.
Working at the heart of the world’s second largest economy, we help clients in both the private and public sectors tackle their biggest challenges, identify new opportunities for expansion and value creation, and apply technologies and solutions that create enduring competitive advantage. Our more than 700 partners, consultants, and research analysts serve privately-owned firms, state-owned enterprises, and multinational companies from across 6 locations: Beijing, Shanghai, Shenzhen, Hong Kong, Chengdu, and Taipei. They are supported by more than 300 professional staff. For more information, please visit: https://www.mckinsey.com.cn/.
At Johnson & Johnson Innovation — JLABS, we are passionate about helping healthcare startups succeed, and that means more than providing state-of-the-art lab space and equipment. Our resident companies have access to a wealth of Johnson & Johnson resources and internal expertise in pharmaceuticals, medical devices and consumer products – and across all of our therapeutic areas. And because it’s a “no-strings-attached” model, companies gain access to the broader Johnson & Johnson Family of Companies and expertise while retaining intellectual property and decision-making freedom. For more information, please visit: https://jnjinnovation.com/jlabs/locations/jlabs-shanghai.
The Touch Foundation
Touch Foundation is a non-for-profit organization funded and led by an Emeritus Director at McKinsey & Co. Touch combines the best of public and private sector approaches and expertise to strengthen health systems in sub-Saharan Africa. Today our programs’ focus extends from ensuring access to emergency transport and high-quality care for obstetric and neonatal emergencies across Sub-Saharan Africa, to using an innovative/ data-driven solution to optimize planning and decision-making around production, deployment and retention of health workers in several countries. Given our deeply-rooted private sector DNA, we are also focused on developing market-based solution for the private sector in health to complement the role of the public health system in providing universal care to their population. For more information, please visit: